The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study

Table 6 Persistence in post-index period in the male LUTS (including OAB) sub-cohort

Index drug	N	Persistence days Median (Q1–Q3)
Monotherapy
Solifenacin	2759	97 (30–365^a)
Oxybutynin	2613	56 (28–363)
Tolterodine	1445	56 (28–359)
Mirabegron	503	205 (50–365^a)
Fesoterodine	285	115 (28–365^a)
Trospium	227	102 (30–365^a)
Flavoxate	49	54 (30–222)
Darifenacin	47	71 (28–365^a)
Propiverine	18	42 (28–273)
Combination drug therapy
Solifenacin + tamsulosin	902	111 (53–365^a)
Oxybutynin + tamsulosin	364	65 (42–195)
Tamsulosin + tolterodine	248	99 (48–335.5)
Finasteride + solifenacin + tamsulosin	233	121 (61–365^a)
Doxazosin + solifenacin	114	117 (59–308)
Solifenacin + tolterodine	114	50 (34–75)
Finasteride + oxybutynin + tamsulosin	111	69 (49–215)
Oxybutynin + solifenacin	102	54 (38–82)
Finasteride + solifenacin	96	120 (55–365^a)
Mirabegron + tamsulosin	96	98 (47–365^a)
Doxazosin + oxybutynin	95	60 (44–128)
Mirabegron + solifenacin	95	61 (42–95)
Fesoterodine + tamsulosin	83	80 (50–221)
Dutasteride + solifenacin + tamsulosin	79	74 (51–235)
Doxazosin + tolterodine	69	95 (50–365^a)
Tamsulosin + trospium	65	144 (61–365^a)
Finasteride + oxybutynin	62	77 (42–240)
Finasteride + tamsulosin + tolterodine	57	119 (62–365^a)
Alfuzosin + solifenacin	47	124 (42–365^a)
Other combinations	1405	63 (41–151)

LUTS: lower urinary tract symptoms; OAB: overactive bladder; Q1: lower quartile; Q3: upper quartile
^aQ3 not reached by 365 days

ISSN: 1471-2490